What is D3 Bio?
D3 Bio operates as a specialized biotechnology enterprise focused on the discovery, development, and registration of novel therapeutic agents. By leveraging advanced clinical insights and biomarker-driven strategies, the company aims to deliver first-in-class or best-in-class medicines. Its core programs are strategically designed to target driver mutations and critical immune pathways, positioning the firm as a high-potential innovator in the global drug development sector. With global rights to its entire portfolio, D3 Bio maintains a robust competitive advantage in the rapidly evolving landscape of precision medicine.
How much funding has D3 Bio raised?
D3 Bio has raised a total of $570M across 3 funding rounds:
Series A
$200M
Series A
$262M
Series B
$108M
Series A (2020): $200M with participation from Boyu Capital, Temasek, Matrix Partners, Sequoia Capital, and WuXi AppTec
Series A (2024): $262M led by Medicxi, Temasek, Boyu Capital, WuXi AppTec, Matrix Partners, and Sequoia Capital
Series B (2025): $108M supported by IDG Capital, Temasek, HSG, and Medicxi
Key Investors in D3 Bio
Temasek
Founded in 1974, Temasek is a global investment company headquartered in Singapore. We are a generational investor, seeking to make a difference always with tomorrow in mind.
Boyu Capital
Boyu is a leading alternative asset management firm founded in 2011, specializing in private equity, public equities, real assets and infrastructure, venture capital, and renewable energy.
Medicxi
Medicxi is a healthcare investment firm that specializes in supporting innovative biotechnology companies, providing financial resources and strategic guidance to advance research and development efforts.
What's next for D3 Bio?
With the successful closure of this major strategic investment, D3 Bio is well-positioned to scale its clinical operations and advance its lead candidates through the regulatory registration process. The company's roadmap focuses on transitioning its oncology and immunology programs from discovery into late-stage clinical trials. By utilizing the newly acquired capital, D3 Bio intends to strengthen its research infrastructure and expand its global footprint, ensuring that its pipeline of clinically meaningful therapies reaches patients in need. The firm remains committed to its long-term vision of transforming patient outcomes through scientific excellence and strategic partnerships.
See full D3 Bio company page
